FY2026 EPS Estimates for Sanofi Reduced by Erste Group Bank

Key Points

• Erste Group Bank trimmed its FY2026 EPS estimate for Sanofi to $4.92 from $4.96 and forecasts FY2027 EPS of $5.21.
• Analyst coverage is mixed — five Buy and nine Hold ratings leave Sanofi with an average rating of "Hold" and a consensus target price of $62.67.
• Sanofi shares opened at $44.55 and were trading down ~1.0%, with a one‑year range of $44.00–$60.12, a market cap of about $108.7B and a P/E of 12.38.

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Erste Group Bank dropped their FY2026 earnings estimates for shares of Sanofi in a report released on Wednesday, March 4th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $4.92 per share for the year, down from their previous forecast of $4.96. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Erste Group Bank also issued estimates for Sanofi's FY2027 earnings at $5.21 EPS.

Several other brokerages have also recently weighed in on SNY. Wall Street Zen cut Sanofi from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 21st. Weiss Ratings reissued a "hold (c)" rating on shares of Sanofi in a report on Monday, December 29th. UBS Group reaffirmed a "neutral" rating on shares of Sanofi in a research note on Friday, January 16th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Bank of America downgraded shares of Sanofi from a "buy" rating to a "neutral" rating in a research note on Thursday, February 12th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Sanofi has an average rating of "Hold" and a consensus target price of $62.67.

Sanofi Trading Down 1.0%

Shares of NASDAQ:SNY opened at $44.55 on Monday. The business's 50 day simple moving average is $47.31 and its 200 day simple moving average is $48.44. Sanofi has a 1 year low of $44.00 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The company has a market capitalization of $108.66 billion, a P/E ratio of 12.38, a P/E/G ratio of 1.15 and a beta of 0.45.

Hedge Funds Weigh In On Sanofi

Several hedge funds and other institutional investors have recently modified their holdings of the business. Caprock Group LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at approximately $1,347,000. Assetmark Inc. increased its position in Sanofi by 25.0% during the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company's stock worth $16,859,000 after purchasing an additional 71,356 shares in the last quarter. Thrivent Financial for Lutherans increased its position in Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company's stock worth $103,846,000 after purchasing an additional 2,178,647 shares in the last quarter. NewEdge Wealth LLC lifted its stake in Sanofi by 63.1% in the 3rd quarter. NewEdge Wealth LLC now owns 67,303 shares of the company's stock valued at $3,298,000 after purchasing an additional 26,035 shares during the last quarter. Finally, Willis Investment Counsel lifted its stake in Sanofi by 11.3% in the 3rd quarter. Willis Investment Counsel now owns 556,700 shares of the company's stock valued at $26,276,000 after purchasing an additional 56,500 shares during the last quarter. Institutional investors own 14.03% of the company's stock.

Sanofi Company Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.